
EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...

Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...

Catalent swallows VMIC Ltd
The biologics development and manufacturing facility taken over from Vaccine Manufacturing and Innovation Centre UK Ltd. is locaterd n to the south...

Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...

Bayer Leaps to invests €1.3bn externally
"We are on the threshold of a new era of innovation in the life sciences." commented Werner Baumann, Chairman of the Board at Bayer...

G7 heads call for decarbonisation of industry
The G7 ministers underlined the importance of efforts to improve energy efficiency, the need for increased investment in renewable energy, tracking...

GSK acquires Sierra Oncology for 1.9bn
GSK is paying $1.9 bn in cash ($55 per share) for the deal. This is a 39 per cent premium to the Sierra share price on 12 April and a 63 per cent...